Leronlimab's main mechanism is to lower inflammati
Post# of 145810
![](/assets/46931549/no_avatar_available_thumb.jpg)
If my thesis that leronlimab can act as a mild anti-viral is correct it is also independent of variation since it affects the virus by inhibiting duplication.
CCR5 blockade of CCL5 disrupts the PI3K/AKT/mTOR/4E-BP1 pathway dysregulating elF4E. With elF4E disrupted the COVID-19 virus 5' -end cap would be unable to separate it's mRNA and duplicate.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)